Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - Systematic review and meta-analysis of randomised controlled trials

Acta Oncologica

Volumn 52, Issue 1, 2013, Pages 18-29

  Gafter Gvili, Anat ^a   Rozen Zvi, Benaya ^a,b   Vidal, Liat ^a,b   Leibovici, Leonard ^a,b   Vansteenkiste, Johan ^c   Gafter, Uzi ^a,b   Shpilberg, Ofer ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRIC GLUCONATE; FERRITIN; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ERYTHROPOIETIN;

CHEMOTHERAPY INDUCED ANEMIA; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HUMAN; IRON THERAPY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSFERRIN BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; HEMATINICS; HEMATOPOIESIS; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871400455     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.702921     Document Type: Review

References (40)

1. V an Belle S, B arrett-Lee P, B irgegard G, Bokemeyer C, Gascon P, et al . The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defi ning the prevalence, incidence, and treatment of anaemia in cancer patients . Eur J Cancer 2004 ; 40 : 2293 - 306 . (Pubitemid 39348881)
2. Weiss G, Goodnough LT. A nemia of chronic disease. N Engl J Med 2005; 352 : 1011 - 23 .
3. Bohlius J, Weingart O, Trelle S, Engert A. C ancer-related anemia and recombinant human erythropoietin - an updated overview . Nat Clin Pract Oncol 2006; 3 : 152 - 64 .
4. Wauters I, V ansteenkiste J. E rythropoiesis-stimulating agents in cancer patients: Refl ections on safety . Expert Rev Clin Pharmacol 2011; 4 : 467 - 76 .
5. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al . Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis . J Natl Cancer Inst 2005; 97 : 489 - 98 . (Pubitemid 40590430)
6. Schrijvers D, De Samblanx H, Roila F. E rythropoiesisstimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use . Ann Oncol 2010; 21(Suppl 5) : v244 - 7 .
7. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, A rcasoy MO, Spivak JL, et al . American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer . J Clin Oncol 2010; 28 : 4996 - 5010 .
8. NCCN. C linical Practice Guidelines in Oncology: Cancerand chemotherapy-induced anemia, version 2 . 2011 . Available at: http://www. nccn. org/professionals/physician- gls/PDF/anemia. pdf 2011 (accessed 2012 February 1)
9. Bokemeyer C, A apro MS, Courdi A, F oubert J, Link H, Osterborg A, et al . EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update . Eur J Cancer 2007; 43 : 258 - 70 . (Pubitemid 46127840)
10. Goodnough L T. E rythropoietin and iron-restricted erythropoiesis . Exp Hematol 2007; 35 : 167 - 72 . (Pubitemid 46427995)
11. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al . Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study . Leukemia 2007; 21 : 627 - 32 . (Pubitemid 46444544)
12. Hedenus M, B irgegard G. T he role of iron supplementation during epoietin treatment for cancer-related anemia . Med Oncol 2009; 26 : 105 - 15 .
13. Henry D.H.P. arenteral iron therapy in cancer-associated anemia . Hematology Am Soc Hematol Educ Program 2010 ; 2010 : 351 - 6 .
14. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al . Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia . J Clin Oncol 2010; 29 : 97 - 105 .
15. Steensma DP, Sasu BJ, Sloan JA, Tomita D, Loprinzi CL, et al . The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial . J Clin Oncol 2011 ASCO Annual meeting proceedings 2011; 29(15 Suppl) : 9031 .
16. Higgins JPT, Green S, editors . C ochrane handbook for systematic reviews of interventions: version 5.1.0. The Cochrane Collaboration, 2011 . Available from http://www. cochranehandbook. org (accessed 2011 December 1)
17. DerSimonian R, L aird N. M eta-analysis in clinical trials. Control Clin Trials 1986; 7 : 177 - 88. (Pubitemid 17189972)
18. Dangsuwan P, Manchana T. B lood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy . Gynecol Oncol 2010; 116 : 522 - 5 .
19. Kim Y T, K im S W, Y oon B S, C ho H J, N ahm E J, K im S H, et al . Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy . Gynecol Oncol 2007; 105 : 199 - 204 . (Pubitemid 46441460)
20. Beguin Y, M aertens J, D e Prijck B, S chots R, F rere P, B onnet C, et al . Darbepoetin-alfa and i. v. iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial . Blood (ASH Annual Meeting Abstracts) 2008; 112 . Abstract 54.
21. Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, et al . A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy . J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007; 25 : 9109 .
22. Henry D H, D ahl NV, Auerbach M, Tchekmedyian S, Laufman LR . Intravenous ferric gluconate signifi cantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy . Oncologist 2007; 12 : 231 - 42 .
23. Pedrazzoli P, F arris A, D el Prete S, D el Gaizo F, F errari D, Bianchessi C, et al . Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron defi ciency treated with darbepoetin alpha . J Clin Oncol 2008; 26 : 1619 - 25 .
24. Auerbach M, B allard H, Trout J R, M cIlwain M, Ackerman A, Bahrain H, et al . Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial . J Clin Oncol 2004; 22 : 1301 - 7 . (Pubitemid 41079845)
25. Auerbach M, Silberstein PT, Webb RT, A veryanova S, Ciuleanu TE, Shao J, et al . Darbepoetin alfa 300 or 500 mcg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia . Am J Hematol 2010; 85 : 655 - 63 .
26. Bastit L, Vandebroek A, A ltintas S, Gaede B, Pinter T, Suto TS, et al . Randomized, multicenter, controlled trial comparing the effi cacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia . J Clin Oncol 2008; 26 : 1611 - 8 .
27. Clarke H, P allister C J. T he impact of anaemia on outcome in cancer . Clin Lab Haematol 2005; 27 : 1 - 13 . (Pubitemid 40293371)
28. Goodnough LT . R isks of blood transfusion. A nesthesiol Clin Nth Am 2005 ; 23 : 241 - 52 . (Pubitemid 40744876)
29. Aapro M, B eguin Y, B irgegard G, G ascon P, H edenus M, Osterborg A . Too-low iron doses and too many dropouts in negative iron trial? J Clin Oncol 2011 ; 29 : e525 - 6 ; author reply e527 - 8.
30. Smith RE, Jr., A apro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, et al . Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study . J Clin Oncol 2008; 26 : 1040 - 50 .
31. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan T J, Smith C, et al . Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia . J Clin Oncol 2007; 25 : 1027 - 32 . (Pubitemid 46596751)
32. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al . Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials . Lancet 2009; 373 : 1532 - 42 .
33. Bennett CL, Silver SM, D julbegovic B, Samaras AT, Blau CA, Gleason KJ, et al . Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia . JAMA 2008; 299 : 914 - 24 . (Pubitemid 351397066)
34. Ludwig H, C rawford J, O sterborg A, V ansteenkiste J, H enry DH, Fleishman A, et al . Pooled analysis of individual patientlevel data from all randomized, double-blind, placebocontrolled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia . J Clin Oncol 2009; 27 : 2838 - 47 .
35. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials . J Cancer Res Clin Oncol 2012; 138 : 179 - 87 .
36. Husain A, M yers J, S elby D, Thomson B, C how E. S ubgroups of advanced cancer patients clustered by their symptom profi les: Quality-of-life outcomes . J Palliat Med 2011; 14 : 1246 - 53 .
37. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis . Am J Kidney Dis 2008; 52 : 897 - 906 .
38. Henry DH, D ahl NV, Auerbach MA. T hrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron . Am J Hematol 2012; 87 : 308 - 10 .
39. The Clinical Trials. gov website, a service of the U.S National institutes of Health. Available from: http://clinicaltrials.gov/ ct2/show/NCT01101399 (accessed 2012 January 17)
40. The Clinical Trials.gov website, a service of the U.S National institutes of Health. Available from: http://clinicaltrials.gov/ ct2/show/NCT01145638 (accessed 2012 January 17)